Cargando…
Ultra-Rapid Virological Response, Young Age, Low γ-GT/ALT-Ratio, and Absence of Steatosis Identify a Subgroup of HCV Genotype 3 Patients Who Achieve SVR with IFN-α(2a) Monotherapy
BACKGROUND AND AIMS: The standard treatment regimen for chronic HCV genotype 3 (HCV-G3) hepatitis consists of PEGylated interferon-α (IFN-α) and ribavirin at varying doses ranging from 400 to 1,200 mg and results in response rates of 80%. However, this therapy has substantial side-effects including...
Autores principales: | Amanzada, Ahmad, Goralczyk, Armin, Moriconi, Federico, Blaschke, Martina, Schaefer, Inga-Marie, van Thiel, David, Mihm, Sabine, Ramadori, Giuliano |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3208815/ https://www.ncbi.nlm.nih.gov/pubmed/21994136 http://dx.doi.org/10.1007/s10620-011-1933-2 |
Ejemplares similares
-
1060. Evaluation of ALT at Sustained Virologic Response (SVR) in Patients with Treated Hepatitis C Virus (HCV) Infection
por: Theppote, Amanda, et al.
Publicado: (2020) -
Erythropoietin rs1617640 G allele associates with an attenuated rise of serum erythropoietin and a marked decline of hemoglobin in hepatitis C patients undergoing antiviral therapy
por: Amanzada, Ahmad, et al.
Publicado: (2014) -
Characterization of the erythropoietin/erythropoietin receptor axis in a rat model of liver damage and cholangiocarcinoma development
por: Moriconi, Federico, et al.
Publicado: (2012) -
SVR Rates of HCV-infected population under PEG-IFN-α/R treatment in Northwest China
por: Li, Yanhua, et al.
Publicado: (2017) -
Case report: 8 years after liver transplantation: de novo hepatocellular carcinoma 8 months after HCV clearance through IFN-free antiviral therapy
por: Ramadori, Giuliano, et al.
Publicado: (2018)